amiodarone has been researched along with Fatty Liver in 25 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone is a commonly used antiarrhythmic drug and can cause liver steatosis." | 3.85 | Hepatic Amiodarone Lipotoxicity Is Ameliorated by Genetic and Pharmacological Inhibition of Endoplasmatic Reticulum Stress. ( Avraham, R; Bantel, H; Cohen, R; Erez, N; Fishman, S; Hubel, E; Manns, M; Shibolet, O; Tirosh, B; Zvibel, I, 2017) |
| "Drug-induced steatohepatitis is a rare form of liver injury known to be caused by only a handful of compounds." | 2.52 | Mechanistic review of drug-induced steatohepatitis. ( Guo, GL; Schumacher, JD, 2015) |
| "Nonalcoholic steatohepatitis (NASH) is defined histopathologically by the presence of macrovesicular steatosis, cellular ballooning, and inflammation." | 2.48 | A myriad of pathways to NASH. ( Larrain, S; Rinella, ME, 2012) |
| "Steatohepatitis is pathologically characterized by zone 3-dominant hepatic steatosis with ballooned hepatocytes and Mallory bodies, zone 3 pericellular and perivenular fibrosis with or without bridging fibrosis, and lobular inflammatory cell infiltration." | 2.43 | [Drug-induced NASH]. ( Onishi, S; Saibara, T, 2006) |
| "Drugs rarely cause steatohepatitis, but amiodarone, perhexiline, and DH, have unequivocally been found to independently induce the histologic picture of alcoholic liver disease or NASH." | 2.42 | Drug-induced steatohepatitis. ( Sanyal, AJ; Stravitz, RT, 2003) |
| " A protocol is presented for dosing the cells with the steatosis-inducing compound amiodarone, along with the conduction of assays for measuring lipid accumulation and mitochondrial function." | 1.51 | The Use of Primary Hepatocytes in Assessment of Drug Safety and Toxicity. ( Guest, PC, 2019) |
| "Treatment with dronedarone 200mg/kg/day had no effect on body weight, serum transaminases and bilirubin, and hepatic mitochondrial function in both wild-type and jvs(+/-) mice." | 1.40 | Hepatic toxicity of dronedarone in mice: role of mitochondrial β-oxidation. ( Bouitbir, J; Donzelli, M; Felser, A; Krähenbühl, S; Morand, R; Schnell, D; Stoller, A; Terracciano, L, 2014) |
| "In conclusion, steatohepatitis-inducing drugs increase cell calcium and activate tissue transglutaminase, which cross-links CK8 to form a molecular scaffold, from which MDB might secondarily arise." | 1.35 | Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation. ( Berson, A; Descatoire, V; Pessayre, D; Robin, MA, 2008) |
| "Amiodarone is a lipophilic drug that concentrates in the liver and usually, over a period of time, leads to toxicity related to drug accumulation." | 1.35 | Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. ( Chang, C; Fiel, MI; Raja, K; Thung, SN, 2009) |
| " Amiodarone led to a dose-dependent decrease in cell viability with an LD50 of 50 micromol/L and increased production of superoxide anion and lipid peroxidation." | 1.34 | Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity. ( Chabli, A; Colin, P; Elimadi, A; Haddad, PS; Ouazzani-Chahdi, A; Spénard, J, 2007) |
| " These findings suggest that both toxic and hypersensitivity liver injury can occur in response to amiodarone." | 1.27 | Amiodarone hepatotoxicity. A clinicopathologic study of five patients. ( Barwick, KW; Batsford, WP; Enriquez, R; Helzberg, J; Josephson, ME; Riely, CA; Rigas, B; Rosenfeld, LE, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| González, IA | 1 |
| Fuller, LD | 1 |
| Zhang, X | 2 |
| Papke, DJ | 1 |
| Zhao, L | 1 |
| Zhang, D | 1 |
| Liao, X | 1 |
| Liu, X | 1 |
| Fiel, MI | 2 |
| Huang, YL | 1 |
| De Gregorio, C | 1 |
| Silva, V | 1 |
| Elorza, ÁA | 1 |
| Léniz, P | 1 |
| Aliaga-Tobar, V | 1 |
| Maracaja-Coutinho, V | 1 |
| Budini, M | 1 |
| Ezquer, F | 1 |
| Ezquer, M | 1 |
| Laukamp, KR | 1 |
| Lennartz, S | 1 |
| Hashmi, A | 1 |
| Obmann, M | 1 |
| Ho, V | 1 |
| Große Hokamp, N | 1 |
| Graner, FP | 1 |
| Gilkeson, R | 1 |
| Persigehl, T | 1 |
| Gupta, A | 1 |
| Ramaiya, N | 1 |
| Hubel, E | 2 |
| Fishman, S | 2 |
| Holopainen, M | 1 |
| Käkelä, R | 1 |
| Shaffer, O | 1 |
| Houri, I | 1 |
| Zvibel, I | 2 |
| Shibolet, O | 2 |
| Erez, N | 1 |
| Avraham, R | 1 |
| Cohen, R | 1 |
| Bantel, H | 1 |
| Manns, M | 1 |
| Tirosh, B | 1 |
| Guest, PC | 1 |
| Zhou, Y | 1 |
| Hua, J | 1 |
| Barritt, G | 1 |
| Liu, Y | 1 |
| Tang, BZ | 1 |
| Tang, Y | 1 |
| Szalowska, E | 1 |
| van der Burg, B | 1 |
| Man, HY | 1 |
| Hendriksen, PJ | 1 |
| Peijnenburg, AA | 1 |
| Vitins, AP | 1 |
| Kienhuis, AS | 1 |
| Speksnijder, EN | 1 |
| Roodbergen, M | 1 |
| Luijten, M | 1 |
| van der Ven, LT | 1 |
| Amacher, DE | 1 |
| Chalasani, N | 1 |
| Felser, A | 1 |
| Stoller, A | 1 |
| Morand, R | 1 |
| Schnell, D | 1 |
| Donzelli, M | 1 |
| Terracciano, L | 1 |
| Bouitbir, J | 1 |
| Krähenbühl, S | 1 |
| Schumacher, JD | 1 |
| Guo, GL | 1 |
| Hoteit, MA | 1 |
| Sanchez, W | 1 |
| Robin, MA | 2 |
| Descatoire, V | 1 |
| Pessayre, D | 2 |
| Berson, A | 1 |
| Raja, K | 1 |
| Thung, SN | 2 |
| Chang, C | 1 |
| Anthérieu, S | 1 |
| Rogue, A | 1 |
| Fromenty, B | 2 |
| Guillouzo, A | 1 |
| von Vital, JM | 1 |
| Karachristos, A | 1 |
| Singhal, A | 1 |
| Thomas, R | 1 |
| Jain, A | 1 |
| Larrain, S | 1 |
| Rinella, ME | 1 |
| Lettéron, P | 1 |
| Sutton, A | 1 |
| Mansouri, A | 1 |
| Stravitz, RT | 1 |
| Sanyal, AJ | 1 |
| Saibara, T | 1 |
| Onishi, S | 1 |
| Ouazzani-Chahdi, A | 1 |
| Elimadi, A | 1 |
| Chabli, A | 1 |
| Spénard, J | 1 |
| Colin, P | 1 |
| Haddad, PS | 1 |
| Bach, N | 1 |
| Schultz, BL | 1 |
| Cohen, LB | 1 |
| Squire, A | 1 |
| Gordon, R | 1 |
| Schaffner, F | 1 |
| Rigas, B | 1 |
| Rosenfeld, LE | 1 |
| Barwick, KW | 1 |
| Enriquez, R | 1 |
| Helzberg, J | 1 |
| Batsford, WP | 1 |
| Josephson, ME | 1 |
| Riely, CA | 1 |
| Mitova, M | 1 |
| Cerný, E | 1 |
| Zeman, K | 1 |
| Bednarík, B | 1 |
| Misurcová, A | 1 |
5 reviews available for amiodarone and Fatty Liver
| Article | Year |
|---|---|
Drug-induced hepatic steatosis.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Retroviral Agents; Anticholesteremic Agents; Antic | 2014 |
Mechanistic review of drug-induced steatohepatitis.
Topics: Amiodarone; Animals; Camptothecin; Chemical and Drug Induced Liver Injury; Disease Models, Animal; F | 2015 |
A myriad of pathways to NASH.
Topics: Amiodarone; Anti-Retroviral Agents; Bacterial Infections; Cannabis; Diet; Fatty Liver; Genetic Disea | 2012 |
Drug-induced steatohepatitis.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antineoplastic Agents, Hormonal; Calcium Channel Blocke | 2003 |
[Drug-induced NASH].
Topics: Amiodarone; Fatty Acids; Fatty Liver; Humans; Oxidation-Reduction; Tamoxifen | 2006 |
20 other studies available for amiodarone and Fatty Liver
| Article | Year |
|---|---|
Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis.
Topics: Amiodarone; Chemical and Drug Induced Liver Injury, Chronic; Fatty Liver; Fatty Liver, Alcoholic; Hu | 2022 |
Administration of Secretome Derived from Human Mesenchymal Stem Cells Induces Hepatoprotective Effects in Models of Idiosyncratic Drug-Induced Liver Injury Caused by Amiodarone or Tamoxifen.
Topics: Amiodarone; Animals; Chemical and Drug Induced Liver Injury; Fatty Liver; Humans; Immunologic Factor | 2023 |
Iodine accumulation of the liver in patients treated with amiodarone can be unmasked using material decomposition from multiphase spectral-detector CT.
Topics: Aged; Aged, 80 and over; Amiodarone; Computed Tomography Angiography; Fatty Liver; Female; Humans; I | 2020 |
Repetitive amiodarone administration causes liver damage via adipose tissue ER stress-dependent lipolysis, leading to hepatotoxic free fatty acid accumulation.
Topics: Adipocytes; Adipose Tissue; Amiodarone; Animals; Endoplasmic Reticulum Stress; Fatty Acid-Binding Pr | 2021 |
Hepatic Amiodarone Lipotoxicity Is Ameliorated by Genetic and Pharmacological Inhibition of Endoplasmatic Reticulum Stress.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; CCAAT-Enhancer-Binding Proteins; Cell Line, Transformed | 2017 |
The Use of Primary Hepatocytes in Assessment of Drug Safety and Toxicity.
Topics: Amiodarone; Animals; Biomarkers; Dose-Response Relationship, Drug; Fatty Liver; Gene Expression Prof | 2019 |
Live Imaging and Quantitation of Lipid Droplets and Mitochondrial Membrane Potential Changes with Aggregation-Induced Emission Luminogens in an in Vitro Model of Liver Steatosis.
Topics: Amiodarone; Fatty Liver; Fluorescence; Fluorescent Dyes; Hep G2 Cells; Humans; Lipid Droplets; Membr | 2019 |
Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.
Topics: Amiodarone; Animals; Enzyme Inhibitors; Extracellular Matrix; Fatty Liver; Gene Expression; Gene Exp | 2014 |
Mechanisms of amiodarone and valproic acid induced liver steatosis in mouse in vivo act as a template for other hepatotoxicity models.
Topics: Amiodarone; Animals; Binding Sites; Cell Line; Chemical and Drug Induced Liver Injury; Disease Model | 2014 |
Hepatic toxicity of dronedarone in mice: role of mitochondrial β-oxidation.
Topics: Alanine Transaminase; Amiodarone; Animals; Anti-Arrhythmia Agents; bcl-2-Associated X Protein; Disea | 2014 |
A bright liver.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Amiodarone; Aspartate Aminotransferases; Bilirubin | 2008 |
Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation.
Topics: Amiodarone; Animals; Calcium; Fatty Liver; GTP-Binding Proteins; Hepatocytes; Hexestrol; Inclusion B | 2008 |
Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Biopsy; Chemical and Drug Induced Liver Injury; Diagnosis, | 2009 |
Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.
Topics: Amiodarone; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Down-Regulation; Fatty Ac | 2011 |
Acute amiodarone hepatotoxicity after liver transplantation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Hepatocellular; C | 2011 |
Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice.
Topics: Amiodarone; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 2003 |
Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity.
Topics: Amiodarone; Animals; Antioxidants; Ascorbic Acid; Butylated Hydroxytoluene; Cells, Cultured; Dose-Re | 2007 |
Amiodarone hepatotoxicity: progression from steatosis to cirrhosis.
Topics: Aged; Amiodarone; Biopsy; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis; Liver Function Tests; | 1989 |
Amiodarone hepatotoxicity. A clinicopathologic study of five patients.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Amiodarone; Aspartate Aminotransferases; Benzofura | 1986 |
[Adverse effects of Cordarone in a study in rats].
Topics: Amiodarone; Animals; Benzofurans; Fatty Liver; Heart; Liver; Lung; Male; Myocardium; Rats; Rats, Inb | 1986 |